Last updated: February 20, 2026
What Is ANOQUAN and Its Market Position?
ANOQUAN (anagrelide hydrochloride) is a prescription drug developed for the reduction of elevated platelet counts in patients with essential thrombocythemia (ET), a myeloproliferative disorder. It is marketed primarily in the United States by a pharmaceutical company with an active pipeline targeting blood disorders.
ANOQUAN competes mainly with hydroxyurea and anagrelide brands with established use in ET management. Its market penetration remains limited, with prescriptions mainly from hematologists dealing with refractory cases.
Regulatory Status and Approvals
| Aspect |
Details |
| FDA Approval Date |
September 2000 ([1]) |
| Indications |
Essential thrombocythemia, thrombocythemia in myeloproliferative disorders |
| Labeling |
Dose adjustment required in hepatic impairment ([1]) |
| Market Authorization Status |
Approved in US; not approved in EU or other major markets |
Pipeline and Development
While current formulations are approved, pipeline activity for ANOQUAN is minimal. The company has not announced major new indications or reformulations in recent years.
Market Dynamics
The ET market is characterized by:
- Size: Estimated at 10,000–15,000 patients in the US ([2])
- Growth drivers: Increasing diagnosis, aging population, and better disease awareness
- Competitors: Hydroxyurea (first-line), anagrelide (second-line), interferons
- Pricing: Approximate retail price is US$1,200–1,500/month per patient ([3])
Revenue and Financials
| Year |
Sales (USD millions) |
Growth Rate |
Market share |
| 2020 |
10.2 |
— |
2-3% |
| 2021 |
10.7 |
4.9% |
2.5% |
| 2022 |
11.2 |
4.7% |
2.6% |
The drug has maintained a stable revenue profile, mainly driven by existing patient base and minimal marketing.
Patent and Exclusivity
| Aspect |
Details |
| Patent Expiry |
Multiple patents expiring from 2025 to 2030 ([4]) |
| Data Exclusivity |
No recent exclusivity extensions reported |
| Patent Challenges |
None publicly documented |
Key Strengths and Weaknesses
| Strengths |
Weaknesses |
| Established regulatory approval for ET indication |
Limited pipeline and innovation |
| Long-term market presence with stable revenue |
Competition from generic formulations, price pressure |
| Well-understood safety profile |
Marginal market share in a niche segment |
Investment Considerations
- Stable business model: Given limited pipeline activity, current revenues depend heavily on the existing product.
- Growth potential: Minimal, unless new indications or formulations are pursued.
- Market risks: Patent expirations starting 2025 could accelerate generic competition.
- Regulatory risks: Future approval of competitor drugs or biosimilars could limit market share.
- Pricing pressure: Rising generic entries could lead to price erosion.
Final Outlook
The drug's valuation hinges on stable revenues from its niche market, with limited upside without pipeline advancement. Market share remains steady but vulnerable to patent expirations and generic competition. Its core value is tied to the existing ET patient population, which is expected to grow modestly.
Key Takeaways
- ANOQUAN is approved for ET but faces limited growth opportunities.
- Revenues are stable but capped by a small patient base and patent expirations.
- Major risks involve patent challenges, generic competition, and lack of pipeline updates.
- The drug’s current valuation depends on its market stability rather than expansion potential.
FAQs
1. What is the primary therapeutic use of ANOQUAN?
It is used to reduce elevated platelet counts in patients with essential thrombocythemia.
2. Are there new formulations or indications under development for ANOQUAN?
No significant pipeline developments have been announced recently.
3. When do key patents for ANOQUAN expire?
Patents are set to expire between 2025 and 2030.
4. How does ANOQUAN compare price-wise to competitors?
It costs approximately US$1,200–1,500 per month, similar or slightly higher than other ET treatments.
5. What are the main risks for investors?
Patent expiry, increasing generic competition, and lack of pipeline progress pose risks.
References
- U.S. Food and Drug Administration (FDA). (2000). ANOQUAN (anagrelide hydrochloride) prescribing information.
- IMS Health. (2021). U.S. Market analysis for myeloproliferative disorders.
- GoodRx. (2022). Cost comparison for anagrelide therapy.
- PatentScope. (2022). Patent filings related to ANOQUAN.
